E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Hand Eczema |
eczema cronico alle mani |
|
E.1.1.1 | Medical condition in easily understood language |
Hand Eczema |
eczema alle mani |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084778 |
E.1.2 | Term | Chronic hand eczema |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term safety of an as-needed treatment with twicedaily applications of delgocitinib cream 20 mg/g. |
Valutare la sicurezza a lungo termine di un trattamento al bisogno con applicazioni due volte al giorno di delgocitinib crema 20 mg/g. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the long-term efficacy of an as-needed treatment with twice-daily applications of delgocitinib cream 20 mg/g. |
Valutare l'efficacia a lungo termine di un trattamento al bisogno con applicazioni due volte al giorno di delgocitinib crema 20 mg/g. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed and dated informed consent has been obtained prior to any protocol related procedures. • The baseline visit in this extension trial must coincide with the Week 16 (end-of-treatment) visit in the parent trial. • Subjects must have met eligibility criteria at screening and baseline in the parent trial. • Subjects must have completed the treatment period in the parent trial (to be assessed at baseline visit in this extension trial). • Subjects must have complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator. • A woman of childbearing potential must use an acceptable method of birth control throughout the trial up until the end-of-treatment/early termination visit. |
Il consenso informato firmato e datato è stato ottenuto prima di qualsiasi procedura relativa al protocollo. • La visita basale in questo studio di estensione deve coincidere con la visita della Settimana 16 (fine trattamento) nello studio originario I soggetti devono aver soddisfatto i criteri di idoneità allo screening e al basale nello studio originario. • I soggetti devono aver completato il periodo di trattamento nello studio originario (da valutare alla visita basale in questo studio di estensione). • I soggetti devono aver rispettato il protocollo dello studio clinico nello studio originario in maniera soddisfacente per lo sperimentatore. • Una donna in età fertile deve utilizzare un metodo accettabile di controllo delle nascite durante l'intero studio fino alla visita di fine trattamento/interruzione anticipata. |
|
E.4 | Principal exclusion criteria |
• Subjects who prematurely discontinued treatment with the investigational medicinal product (IMP) or initiated rescue medication in the parent trial. • Subjects who experienced any AE during participation in the parent trial, which precludes further treatment with delgocitinib cream 20 mg/g in the judgement of the investigator. • Any medical or psychiatric condition that could put the subject at undue risk by participating in the trial, or which, by the investigator's judgment, makes the subject inappropriate for the trial. • Current participation in any other interventional clinical trial, except for parent trials. |
Soggetti che hanno interrotto prematuramente il trattamento con il medicinale sperimentale (IMP) o che hanno iniziato un farmaco di salvataggio (rescue medication) nello studio originario. • Soggetti che hanno manifestato qualsiasi EA durante la partecipazione allo studio originario, che a giudizio dello sperimentatore precluda un ulteriore trattamento con delgocitinib crema 20 mg/g. • Qualsiasi condizione medica o psichiatrica che potrebbe esporre il soggetto a un rischio indebito a seguito della partecipazione allo studio o che, a giudizio dello sperimentatore, renda il soggetto inadatto allo studio. • Attuale partecipazione a qualsiasi altro studio clinico interventistico, ad eccezione degli studi originari. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of treatment-emergent AEs from baseline up to Week 38 |
Numero di eventi avversi (EA) emergenti dal trattamento dal basale fino alla Settimana 38. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
IGA-CHE score at each scheduled visit from baseline up to Week 36. • IGA-CHE score of 0 (clear) or 1 (almost clear) at each scheduled visit from baseline up to Week 36. • HECSI score at each scheduled visit from baseline up to Week 36. • HECSI-75 at each scheduled visit from baseline up to Week 36. • HECSI-90 at each scheduled visit from baseline up to Week 36. |
Punteggio IGA-CHE1 a ogni visita programmata dal basale fino alla Settimana 36. • Punteggio IGA-CHE di 0 (pelle intatta) o 1 (pressoché intatta) a ogni visita programmata dal basale fino alla Settimana 36. • Punteggio HECSI2 a ogni visita programmata dal basale fino alla Settimana 36. • Punteggio HECSI-75 a ogni visita programmata dal basale fino alla Settimana 36. • Punteggio HECSI-90 a ogni visita programmata dal basale fino alla Settimana 36 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Timepoint for evaluation described in each endpoint. |
Timepoint per la valutazione descritto in ciascun endpoint. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 81 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Belgium |
Denmark |
France |
Germany |
Italy |
Netherlands |
Poland |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 2 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 2 |